insights_auto
Why is AXGN down ५.४७%?
Dive Deeperchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
US$ ४८.५४
arrow_downward
-५.४७%(-२.८१) 1D
नोभेम्बर ५, १२:१८:५६ GMT-५ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
US$ ५१.६२
High
US$ ५१.८५
Low
US$ ४८.३०
Mkt. cap
२.९० अरब
Avg. vol.
१७.८० लाख
Volume
४.०९ लाख
52-wk high
US$ ५२.९१
52-wk low
US$ २३.००
EPS
-US$ ०.६८
Beta
१.२१
Shares outstanding
५.९७ करोड
No. of employees
६२२
Open
US$ ५१.६२
High
US$ ५१.८५
Low
US$ ४८.३०
Mkt. cap
२.९० अरब
Avg. vol.
१७.८० लाख
Volume
४.०९ लाख
52-wk high
US$ ५२.९१
52-wk low
US$ २३.००
EPS
-US$ ०.६८
Beta
१.२१
Shares outstanding
५.९७ करोड
No. of employees
६२२
News stories
From web sources and news partners
Quartz
·
१४ मिनेट पहिले
Bitcoin falls to seven-week low as tech selloff hits crypto
CNBC
·
१५ मिनेट पहिले
Jim Cramer says the AI trade is not going away as Nasdaq enters correction
The Block
·
२६ मिनेट पहिले
Canary's Injective ETF debuts on Nasdaq with exposure to staking rewards
ABC News - Breaking News, Latest News and Videos
·
१४ मिनेट पहिले
Dow plunges 1,200 points, shedding most of midterm results stock rally
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees६२२
Founded२००२
HeadquartersAlachua, फ्लोरिडा, संयुक्त राज्य अमेरिका
Sector-
Industry-
Websiteaxogeninc.com